Optical Simulation Of Changing The Diopter Of Acrylate Intraocular Lens Based On Femtosecond Laser

ZEMAX optical software was employed to simulate the femtosecond laser scanning of the intraocular lens(IOL), with the objective of fabricating a novel lens within the existing intraocular lens. This approach was undertaken to evaluate the feasibility of altering the power of the IOL.

Optical simulation

The pseudophakic eye model was developed using the optical simulation software ZEMAX. A single lens or a diffractive lens with a diameter of 4 mm was integrated within the IOL. The refractive index of the new lens is an assumed value. The parameters for the IOL were derived from a standard commercially available 21 diopter(D) hydrophobic acrylate IOL, encompassing specifications such as refractive index and the curvature of the anterior and posterior surfaces. The optical path design underwent optimization, and the imaging quality was subsequently assessed using the Modulation Transfer Function (MTF) and spherical aberration analysis.

By constructing the pseudophakic eye model for optical simulation, creating a diffractive lens or a single lens inside the IOL can reduce its diopter of by 1D-5D on the basis of the original. The magnitude of the change in diopter is related to the pattern design.

In summary, the ZEMAX optical simulation has demonstrated the potential of employing femtosecond laser scanning on IOLs to fabricate a novel lens within the IOL, thereby altering its refractive power. The diopter of an IOL can be adjusted by incorporating either a single convex lens or a diffractive lens of specific dimensions within the IOL. When aiming for the same diopter change, the diffractive lens design occupies a smaller area compared to the single convex lens.This finding paves the way for subsequent in vitro investigations by our research group. According to the current optical simulation data, a modification of 0.005 in the refractive index of the IOL can result in a maximum alteration of 5D in the standard 21D IOL.